News
-
-
COMMUNIQUÉ DE PRESSE
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire initiates Phase 1 trial for high-dose aspirin formulation to target acute myocardial infarction. Trial to evaluate safety, pharmacokinetics, pharmacodynamics, with fast track FDA application -
-
-
COMMUNIQUÉ DE PRESSE
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Aspire announces completion of GMP Clinical Batch for high-dose sublingual aspirin with fast-acting formulation. Company to commence bioavailability study in April 2025 and request 'fast track' FDA approval -
-
-
COMMUNIQUÉ DE PRESSE
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Aspire Biopharma Holdings, Inc. provides update on patent applications for Oral Mucosal Formulations of Aspirin with rapid absorption technology. Company aims to revolutionize drug delivery and improve patient outcomes -
-
